Short answer: yes, there is a peptide called KPV, and it is not the same as BPC-157. KPV is a three-amino-acid peptide, lysine-proline-valine, that corresponds to the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). BPC-157 is a 15-amino-acid peptide derived from a gastric protein sequence. They come from different places, differ enormously in size, are studied in largely different experimental models, and share one weakness: both rest mostly on animal work. This guide sets out the differences side by side so that a researcher can see what each literature actually contains. It is for laboratory readers, it is not use advice, and nothing here describes use in people.
Where KPV comes from
α-MSH is a 13-residue peptide hormone, and its last three residues are Lys-Pro-Val, which gives KPV its name. The tripeptide was characterised as a fragment of that hormone with anti-inflammatory activity in experimental systems, and it has been examined as a small molecule that does not need the full hormone’s receptor profile. Our existing entry on the KPV peptide gives the background, and the KPV product page describes the form supplied for laboratory research.
If you want the wider melanocortin context, our comparison of Melanotan 1 and Melanotan 2 explains how α-MSH analogues are built and why receptor selectivity matters. KPV sits at the opposite end of that design space: not a longer, more stable hormone analogue, but the shortest active-looking fragment.
What the KPV literature contains
Much of the evidence for KPV comes from models of intestinal inflammation. Two papers anchor it.
- Dalmasso et al. (Gastroenterology, 2008), titled “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation”, reported that KPV was taken up by the peptide transporter PepT1 and that this was associated with reduced inflammation in experimental colitis.
- Kannengiesser et al. (Inflammatory Bowel Diseases, 2008) reported that the melanocortin-derived tripeptide KPV had anti-inflammatory potential in murine models of inflammatory bowel disease.
Two features of these papers shape how they should be read. The transport route matters: a tripeptide that uses PepT1, a transporter expressed in the intestinal epithelium, behaves differently from a large peptide that relies on other routes, and the findings are tied to that mechanism. The models also matter: colitis in mice is an inflammation model with its own limitations, and success there does not predict outcomes elsewhere. As far as we are aware, the KPV literature is smaller and narrower than the BPC-157 literature, and it has not been tested at scale outside those models.
What the BPC-157 literature contains
BPC-157 is a pentadecapeptide, 15 residues long, and its literature is both bigger and more concentrated. Representative studies include Staresinic et al. (Journal of Orthopaedic Research, 2003) on healing of transected rat Achilles tendon and Staresinic et al. (2006) on rat quadriceps muscle. A systematic review, Vasireddi et al. (HSS Journal, 2025), identified 36 studies, of which 35 were preclinical and one was clinical, and reported that no clinical safety data were found. Our BPC-157 research hub gathers these papers, and BPC-157 for laboratory research lists the material we supply.
The usual caveats for this literature apply: most work comes from one group, the animal numbers are often small, and independent replication has been limited. BPC-157 is also on the World Anti-Doping Agency Prohibited List under non-approved substances.
A side-by-side comparison
- Size: KPV is a tripeptide; BPC-157 is a pentadecapeptide. That alone changes transport, stability and manufacturing.
- Origin: KPV is the C-terminal fragment of α-MSH; BPC-157 is derived from a sequence in a gastric protein.
- Best-known models: KPV in intestinal inflammation (colitis) models; BPC-157 mainly in tendon, muscle and other injury models in rats.
- Transport: KPV has been linked to the peptide transporter PepT1 in intestinal cells; BPC-157 literature does not centre on a single transporter.
- Clinical evidence: limited for both. BPC-157’s one clinical report is a small retrospective series; we are not aware of controlled clinical trials of KPV that would change that summary.
- Anti-doping status: BPC-157 is listed; KPV is not specifically named in the sources we reviewed, but the list is “including, but not limited to”, so athletes should consult the current WADA document.
What the two literatures have in common
Both share the usual problems of preclinical peptide research. Species, dose, route and model differ between studies, so results are difficult to compare. Publication bias is hard to assess. And neither literature supports claims about outcomes in people. That does not make the research worthless. It means that the right use of both bodies of work is to generate hypotheses and design controlled experiments, not to treat the results as settled.
It also means that mixing the two in a single experiment adds a confounder. If a study wants to ask whether KPV and BPC-157 interact, it needs groups for each peptide alone and for the combination, as in the rat study of BPC-157 and TB-500 discussed in our Wolverine guide. The same logic applies to any pair.
Practical points for laboratories
- Be exact about sequence. KPV is Lys-Pro-Val; check the certificate states the sequence and the salt form.
- Short peptides are small in mass. A tripeptide has a molecular weight of a few hundred daltons, so a milligram is a large molar amount. Use the peptide calculator and double-check units; our molarity guide has worked examples.
- Verify the batch. Both peptides are supplied by Peptides Lab UK with batch-matched certificates, and all batches are HPLC & COA Verified. For a short, polar peptide such as KPV, check how the HPLC method handles retention, since very small peptides can elute early.
- Use equimolar comparisons. The concentration maths for that is in our molarity guide.
- Plan controls for transporter-dependent effects. If PepT1 is relevant to your model, include a transporter control; the cell line’s expression will affect the result.
Why a tripeptide and a fifteen-mer behave so differently
PepT1 is a proton-coupled transporter that carries di- and tripeptides across epithelial membranes. That is a structural reason why KPV, a tripeptide, is a natural candidate for that route and why a 15-residue peptide would not use it in the same way. Size also affects almost everything a chemist cares about: a tripeptide has a molecular weight of a few hundred daltons, is poorly retained on many HPLC columns, and has few sites for degradation, whereas a pentadecapeptide has more bonds that peptidases can attack and more conformational freedom. BPC-157 is described in the literature as unusually stable in gastric juice, a property usually attributed to its origin in a gastric protein; that claim comes largely from the same group that developed the peptide, so it is worth treating as a reported property awaiting independent confirmation. Differences of this kind are the reason the two compounds cannot be compared on potency alone.
Designing a fair head-to-head comparison
A laboratory that wants to compare the two should decide first what question it is asking. If the question is about intestinal epithelial inflammation, a colitis model or a cultured epithelial monolayer with a transporter-expressing line is the natural setting, and KPV has the head start. If the question is about tendon or muscle repair, the existing literature is mostly BPC-157 and the comparison is less balanced. Use equimolar rather than equal-mass concentrations, because a milligram of a tripeptide contains several times more molecules than a milligram of a fifteen-mer. Include vehicle and scrambled-sequence controls, record the batch certificates for both peptides, and pre-specify the endpoints. A comparison that equalises mass will usually favour the smaller molecule for trivial reasons, and a comparison that picks the endpoint after seeing the data will favour whichever peptide happened to move.
Reading the anti-inflammatory claims with care
“Anti-inflammatory” is a broad label that covers many different readouts: reduced cytokine expression, lower tissue myeloperoxidase activity, improved histology scores, or better clinical scores in an animal. A paper may report one of these and the headline may imply all of them. When reading either literature, look for which readout moved, in which tissue and at what time point, and whether the effect depended on the experimental inflammatory trigger used. A peptide that dampens one trigger may do nothing against another. Look also for whether the authors tested a scrambled or reversed sequence, which shows whether the effect depends on the specific amino-acid order, and for any attempt to identify the receptor or transporter responsible. These details separate a mechanism from a correlation.
Frequently asked questions
If you are weighing UK peptides suppliers, our guide to buying peptides in the UK and the best research peptides UK scorecard explain what documentation to look for.
Is there a peptide called KPV?
Yes. KPV is a tripeptide, lysine-proline-valine, corresponding to the C-terminal end of α-melanocyte-stimulating hormone. It has been studied in experimental models of intestinal inflammation.
What are the differences between KPV and BPC-157?
KPV is a three-residue fragment of α-MSH studied mainly in colitis models and linked to PepT1 uptake. BPC-157 is a 15-residue peptide derived from a gastric protein sequence studied mainly in rat injury models. Both rest largely on animal work.
Is KPV the same as BPC-157?
No. They have different sequences, sizes and origins, and they have been studied in largely different experimental systems.
Who shouldn’t take KPV peptide?
Peptides Lab UK supplies KPV for laboratory research only and does not give advice on use in people. KPV is not a licensed medicine, and anyone with a health question should speak to a qualified clinician.
Has KPV been tested in people?
We are not aware of controlled clinical trials of KPV that would support claims about outcomes in people. The best-known papers are in cells and mouse models of intestinal inflammation.
Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article is educational and is not medical advice.